Hauschild A., Santinami M., Long G. V., Atkinson V., Mandala M., Sileni V. C., Nyakas M. S., Dutriaux C., Haydon A., Robert C., Mortier L., Schachter J., Ji R., Zhang P., Mookerjee B., Legos J., Kefford R., Dummer R., Kirkwood J.   COMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K-mutant melanoma.  Ann. Oncol..  2017 ;28
Grob J. J., Hansson J., Basset-Seguin N., Kunstfeld R., Dreno B., Mortier L., Ascierto P., Licitra L., Hertig C., Dimier N., Fittipaldo A., Hauschild A.   Predicting response to vismodegib before treatment initiation based on baseline characteristics in patients with metastatic basal cell carcinoma in a pooled analysis.  J. Eur. Acad. Dermatol. Venereol..  2017 ;31 :80-81
Frouin F., Melodelima D., de la Chapelle M. L., Vermandel M.   Reporting New Methods and New Results in Biomedical Engineering: Why Not Choosing IRBM?.  IRBM.  2017 ;38 :1-2
Dupont C., Reyns N., Mordon S., Vermandel M.   Photodynamic Therapy in Neurosurgery: A Proof of Concept of Treatment Planning System.  -.  2017 ;10047
Dupont C., Reyns N., Deleporte P., Mordon S. R., Vermandel M.   CHARACTERIZATION OF A NOVEL DEVICE FOR INTRAOPERATIVE PHOTODYNAMIC THERAPY IN NEUROSURGERY.  Lasers Surg. Med..  2017 ;49 :50-50
Dupont C., Reyns N., Deleporte P., Mordon S., Vermandel M.   Intraoperative Photodynamic Treatment for High-Grade Gliomas.  -.  2017 ;10047
Dupont C., Betrouni N., Mordon S. R., Reyns N., Vermandel M.   5-ALA Photodynamic Therapy in Neurosurgery, Towards the Design of a Treatment Planning System: A Proof of Concept.  IRBM.  2017 ;38 :34-41
Davies M. A., Robert C., Long G. V., Grob J. J., Flaherty K. T., Arance A., Chiarion-Sileni V., Thomas L., Lesimple T., Mortier L., Moschos S. J., Hogg D., Rodas I. M., Del Vecchio M., Lebbe C., Meyer N., Zhang Y., Huang Y., Mookerjee B., Saiag P.   COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600-mutant (mut) melanoma brain metastases (MBM).  J. Clin. Oncol..  2017 ;35 :9506-9506
Cornelis F., Ambrosetti D., Rocher L., Derchi L. E., Renard B., Puech P., Claudon M., Rouvière O., Ferlicot S., Roy C., Yacoub M., Grenier N., Bernhard J. C.   CT and MR imaging features of mucinous tubular and spindle cell carcinoma of the kidneys. A multi-institutional review.  Eur. Radiol..  2017 ;27 :1087-1095

Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney is a recently identified renal malignancy. Diagnosis of this rare subtype of renal tumour can be challenging for pathologists, and as such, any additional data would be helpful to improve diagnostic reliability. As imaging features of this new and rare sub-type have not yet been clearly described, the purpose of this study was to describe the main radiologic features on computed tomography (CT) and magnetic resonance imaging (MRI), based jointly on the literature and findings from a multi-institutional retrospective review of pathology and imaging databases. Using a combination of CT/MRI features, diagnosis of MTSCC could be suggested in many cases. A combination of slow enhancement with plateau on dynamic contrast-enhanced CT/MRI, intermediate to high T2 signal intensity contrasting with low apparent diffusion coefficient values on MRI appeared evocative of this diagnosis. KEY POINTS: * A slow enhancement with plateau is observed either on CT or MRI. * High T2 signal components but low apparent coefficient diffusion are evocative. * T2-weighted imaging features depend on the mucin components of the tumour.

Corcoran N. M., Heidenreich A., Shore N., Villers A., Klotz L., Siemens D. R., van Os S., Baron B., Wang F., Chowdhury S.   Prognostic Factors in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide (ENZA) Or Bicalutamide (BIC) in Terrain.  Asia-Pac. J. Clin. Oncol..  2017 ;13 :57-57